CTIS2023-509885-39-00进行中（未招募）1 期
Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patients - PORT
Stichting Radboud University Medical Center0 个研究点目标入组 130 人开始时间: 2023年11月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •The patient has provided informed consent for study participation prior to all trial-related procedures., The patient has a diagnosis of pulmonary tuberculosis according to the local diagnostic criteria., The patient is aged 18 years or older at the day of informed consent., No known allergic reactions or toxicity to rifampicin in the past., Female patients of childbearing potential must have a negative serum pregnancy test, and consent to practice an effective method of birth control during the study. And they should not be lactacting during the trial (female participants of childbearing potential only)., The patient will be compliant to the study schedule, in the discretion of the investigator., For France only: the patient is affiliated to a social security system (as beneficiary) or has state medical aid (Aide Médical d’Etat, AME) or has an ongoing demand for state medical aid (AME) or has an ongoing demand for an emergency medical care (dispositif de soins d'urgence, as applicable for tuberculosis).
排除标准
- •The patient has tuberculosis which is assessed to receive high dose rifampicin according to national guidelines., Known allergy or intolerance for rifamycins., The participant has a known or suspected, current alcohol or drug or amphetamine abuse, that is, in the opinion of the investigator, sufficient to compromise the safety or cooperation of the patient., The patient has a known allergy or intolerance, or concomitant disorders or conditions for which rifamycins or other standard TB treatment drugs are contraindicated., The patient has had treatment with any other investigational drug within 1 month prior to enrolment, or enrolment into other clinical (intervention) trials is planned in the upcoming 6 months., Laboratory: at screening one or more of the following abnormalities were observed for the patient in screening laboratory: Serum amino aspartate transferase (AST) and/or serum alanine aminotransferase (ALT) activity >3x the upper limit of normal, Serum total bilirubin level >2.5 times the upper limit of normal, Creatinine clearance (CrCl) level lower than 30 mls/min, Acute or severe or life-threatening liver disease induced by drugs in the past, The patient has a chronic disorder such as liver disease or renal disease., The patient has icterus., Previous anti-TB treatment: the patient ended a previous TB treatment (episode) within last 3 months., The patient started current TB treatment more than 4 weeks ago., The patient has TB meningitis., The patient is in a coma., Circumstances that raise doubt about free, uncoerced consent to study participation (e.g. in a prisoner or mentally handicapped person)., The patient is not able to give consent personally., Poor general condition or comorbidities where delay in treatment cannot be tolerated or death within three months is likely. Or if there is concurrent treatment that may interfere., The patient is pregnant or breast-feeding., Patient infected with a rifampicin-resistant strain of M. tuberculosis.
研究者
相似试验
进行中（未招募）
1 期
High dose rifampicin for tuberculosis, PORTMedDRA version: 20.0Level: PTClassification code 10037440Term: Pulmonary tuberculosisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 25.1Level: LLTClassification code 10087871Term: Drug-sensitive pulmonary tuberculosisSystem Organ Class: 10021881 - Infections and infestationsTuberculosisEUCTR2022-000632-27-DKRadboud University Medical Center164
尚未招募
3 期
Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patientstuberculosis10028440NL-OMON53704Radboud Universitair Medisch Centrum25
进行中（未招募）
1 期
High dose rifampicin for tuberculosis, PORTTuberculosisEUCTR2022-000632-27-NLRadboud University Medical Center164
未知
1 期
Phase 1 Study of BMS-986148Solid tumorsJPRN-jRCT2080223357Bristol-Myers Squibb K.K.15
未知
1 期
Study of BMS-986012 in Subjects With Small Cell Lung CanerSmall Cell Lung CancerJPRN-jRCT2080223369Bristol-Myers Squibb K.K.18